NewLink Genetics Announces Results from Phase 3 IMPRESS Trial of Algenpantucel-L for Patients with Resected Pancreatic Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
SunTrust Downgrades NewLink Genetics (NLNK) to Neutral
May 11, 2016 6:49 AM EDTSunTrust Robinson Humphrey downgraded NewLink Genetics (NASDAQ: NLNK) from Buy to Neutral with a price target of $12.00 (from $59.00).
For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.
Shares of NewLink Genetics closed at $11.45 yesterday.
... MoreMizuho Securities Cuts Price Target on NewLink Genetics (NLNK) Following Failed IMPRESS Trial
May 10, 2016 1:22 PM EDTMizuho Securities maintained a Buy rating on NewLink Genetics (NASDAQ: NLNK), and cut the price target to $20.00 (from $52.00), following a failed IMPRESS Phase III trial.
Analyst Eric Criscuolo commented, "We reiterate our Buy rating but lower our PT from $52 to $20... More
Baird Highlighgs NewLink Genetics' (NLNK) IDO Program Amid Algenpantucel-L Failure
May 10, 2016 6:29 AM EDTBaird analyst Michael Ulz cut his price target on NewLink Genetics (NASDAQ: NLNK) to $23.00 (from $27.00) after Algenpantucel-L (cancer vaccine) failed to demonstrate a benefit in resected pancreatic cancer, with the control arm performing better than expected, as we they had cautioned. However, the firm... More
